Clinical Study
Subconjunctival Bevacizumab Injection in Glaucoma Filtering Surgery: A Case Control Series
Table 4
Comparison in the reduction of IOP and medications in both subconjunctival bevacizumab (SCB) and control groups.
| | SCB group
| Control group
| value |
| Final IOP (mmHg) | 14.0 ± 4.7 | 11.9 ± 4.7 | 0.36 | Percentage of IOP reduction | 20% | 36% | 0.73 | Final number of medications | 0.7 ± 1.1 | 0.4 ± 0.8 | 0.11 | Percentage of the reduction of medication use | 32% | 27% | 0.15 |
|
|